Alternative Data for Grifols
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 50 | Sign up | Sign up | Sign up |
| Webpage traffic | 318,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 919 | Sign up | Sign up | Sign up |
| X Mentions | 5 | Sign up | Sign up | Sign up |
| News Mentions | 2 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Grifols
Grifols, SA is dedicated to obtaining, manufacturing, preparing and selling therapeutic products, mainly blood derivatives. The company is headquartered in Barcelona, Spain.
| Price | $7.81 |
| Target Price | Sign up |
| Volume | 722,073 |
| Market Cap | $7.65B |
| Year Range | $7.81 - $10.74 |
| Dividend Yield | 2.02% |
| PE Ratio | 13.81 |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
Health Coalition demands disclosures & end to Grifols’ for-profit blood plasma contract following reports of deaths, harm, non-complianceMarch 13 - GlobeNewswire |
|
Media Advisory: Press Conference Regarding Tragic Deaths After Plasma Harvesting at Grifols’ SitesMarch 12 - GlobeNewswire |
|
Plasbumin-5 (Grifols Therapeutics) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035FMarch 10 - GlobeNewswire |
|
Albuked (Kedrion Biopharma, Grifols) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035FMarch 10 - GlobeNewswire |
|
Plasbumin-25 (Grifols) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035FMarch 10 - GlobeNewswire |
|
Albuminar-25 (Grifols) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035FMarch 10 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 1.87B | 1.11B | 752M | 127M | 457M | 0.218 |
| Q2 '25 | 1.89B | 1.15B | 744M | 117M | 347M | 0.220 |
| Q1 '25 | 1.79B | 1.08B | 705M | 60M | 405M | 0.092 |
| Q4 '24 | 1.98B | 1.21B | 766M | 69M | 337M | 0.108 |
| Q3 '24 | 1.79B | 1.07B | 727M | 52M | 425M | 0.170 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about Grifols (GRFS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions & customer reviews.
FAQ - Grifols
The Market Cap of Grifols is $7.65B.
As of today, Grifols' PE (Price to Earnings) ratio is 13.81.
Currently, the price of one share of Grifols stock is $7.81.
The GRFS stock price chart above provides a comprehensive visual representation of Grifols' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Grifols shares. Our platform offers an up-to-date GRFS stock price chart, along with technical data analysis and alternative data insights.
Yes, Grifols (GRFS) offers dividends to its shareholders, with a dividend yield of 2.02%. This dividend yield represents Grifols' commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Grifols in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
Some of the similar stocks of Grifols are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
